↑ トップへ ← 戻る

 Drug(薬物リスト) ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

60 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   AR-42  1件: Ar-42;   -   -   -   1件:
34
 2   Acetaminophen  8件: Acetaminophen; Acetaminophen tab 650mg; Acetaminophen/paracetamol; Acetaminophen tablets; Paracetamol (acetaminophen); Tramadol hydrochloride + acetaminophen; Oxycodone/acetaminophen; Tramadol /acetaminophen;   D00217   2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   13件:
3,
6,
13,
34,
35,
46,
49,
51,
70,
86,
231,
256,
271
 3   Acetylsalicylic acid  2件: Acetylsalicylic acid; Acetylsalicylic acid at 1st visit,;   D00109   2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   10件:
13,
22,
34,
46,
49,
51,
86,
113,
158,
231
 4   Aminolevulinic acid  3件: Aminolevulinic acid; Levulan (5-aminolevulinic acid) photodynamic therapy.; Levulan (5-aminolevulinic acid) uptake.;   D02908
 D07567 
 -   -   2件:
34,
286
 5   Axitinib  1件: Axitinib;   D03218   3件: FLT1, FLT4, KDR   3件: MAPK signaling pathway, Pathways in cancer, VEGF signaling pathway   1件:
34
 6   Bevacizumab  4件: Bevacizumab; Bevacizumab (genitical recombination); Bevacizumab (avastin) and imatinib mesylate (gleevec); Submucosal bevacizumab;   D06409   1件: VEGFA   3件: Pathways in cancer, Renal cell carcinoma, VEGF signaling pathway   9件:
13,
34,
85,
86,
87,
89,
227,
280,
331
 7   Binimetinib  1件: Binimetinib;   D10604   2件: MAP2K1, MAP2K2   3件: MAPK signaling pathway, Melanoma, Pathways in cancer   1件:
34
 8   Butyric Acid  0件:   D05866   -   -   5件:
34,
51,
56,
97,
291
 9   Cabozantinib  1件: Cabozantinib;   D10062   9件: FLT1, FLT3, FLT4, KDR, KIT, MET, NTRK2, RET, TEK   5件: MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Ras signaling pathway, VEGF signaling pathway   1件:
34
 10   Carboplatin  1件: Carboplatin;   D01363   -   -   4件:
28,
34,
60,
85
 11   Cediranib  2件: Cediranib; Cediranib maleate;   D08881   3件: FLT1, FLT4, KDR   3件: MAPK signaling pathway, Pathways in cancer, VEGF signaling pathway   1件:
34
 12   Celecoxib  7件: Celecoxib; Fixed dose combination ciprofloxacin/celecoxib; Celecoxib (celebrex); Celecoxib 200mg capsule; Celecoxib 200 milligrams; Celecoxib 400 milligrams; Celecoxib, celebrex®;   D00567   1件: PTGS2   1件: Arachidonic acid metabolism   9件:
2,
3,
34,
46,
70,
89,
96,
161,
271
 13   Cetuximab  1件: Cetuximab;   D03455   1件: EGFR   3件: ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   5件:
34,
51,
86,
89,
331
 14   Chloride ion  0件:   -   -   -   17件:
6,
11,
13,
14,
34,
46,
51,
96,
97,
127,
168,
193,
227,
228,
288,
297,
299
 15   Cholecalciferol  9件: Cholecalciferol; Cholecalciferol, vitamin d3; Calcium and cholecalciferol; Cholecalciferol and c. xanthorrhiza; Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol concentrate; 5000 iu of cholecalciferol; Cholecalciferol (vitamin d3);   D00188   1件: VDR   2件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption   15件:
6,
13,
19,
20,
34,
46,
49,
53,
60,
65,
96,
97,
228,
298,
299
 16   Dabrafenib  1件: Dabrafenib;   D10064   1件: BRAF   3件: ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   1件:
34
 17   Dexmedetomidine  8件: Dexmedetomidine; Dexmedetomidine hydrochloride infusion; Dexmedetomidine group; Dexmedetomidine hydrochloride; Dexmedetomidine and fentanyl; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3;   D00514
 D01205 
 3件: ADRA2A, ADRA2B, ADRA2C   1件: Neuroactive ligand-receptor interaction   11件:
2,
4,
6,
21,
34,
70,
113,
212,
215,
226,
280
 18   Diclofenac  9件: Diclofenac; Diclofenac sodium topical gel; Diclofenac sodium; Comparator: diclofenac; Comparator: diclofenac sodium; Diclofenac + omeprazole; Diclofenac natrium pch retard tablet mga 75mg; Diclofenac 50 milligrams; Diclofenac sr;   D00903
 D00904
 D07816 
 2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   4件:
13,
34,
46,
271
 19   Doxorubicin  4件: Doxorubicin; Doxorubicin hydrochloride; 4'-iodo-4'-deoxydoxorubicin; Liposomal doxorubicin;   D03899   -   -   6件:
26,
28,
34,
61,
63,
331
 20   Etoposide  2件: Etoposide; Carmustine, etoposide, cytarabine, and melphalan (beam);   D00125
 D04107 
 -   -   11件:
11,
13,
14,
26,
28,
34,
60,
65,
85,
164,
331
 21   Everolimus  6件: Everolimus; Everolimus (rad001); Everolimus (rad001) , afinitor®; Rad001, everolimus; Rad001: everolimus; Afinitor (everolimus);   D02714   1件: MTOR   4件: Breast cancer, ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   9件:
34,
67,
89,
96,
137,
157,
158,
228,
277
 22   Filgrastim  7件: Filgrastim; Pegfilgrastim; Ep2006 (filgrastim); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim); Filgrastim (g-csf);   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   28件:
2,
6,
13,
16,
25,
26,
28,
34,
35,
36,
40,
41,
42,
45,
46,
49,
51,
60,
62,
65,
85,
96,
113,
164,
283,
284,
285,
331
 23   Fludeoxyglucose F-18  0件:   -   -   -   8件:
6,
13,
34,
46,
53,
84,
127,
300
 24   Gadolinium  6件: Gadolinium; Gadolinium-based contrast; Standard gadolinium contrast; Gadolinium contrast; Gadolinium for abdomen; Gadolinium for lower back;   -   -   -   6件:
13,
34,
46,
58,
65,
305
 25   Gadopentetic acid  0件:   D01707
 D08006 
 -   -   1件:
34
 26   Icotinib  1件: Icotinib;   D11251   1件: EGFR   2件: EGFR tyrosine kinase inhibitor resistance, Pathways in cancer   1件:
34
 27   Ifosfamide  1件: Ifosfamide;   D00343   -   -   1件:
34
 28   Imatinib  6件: Imatinib; Imatinib mesilate; Imatinib mesylate; Imatinib mesylate (gleevec); Bevacizumab (avastin) and imatinib mesylate (gleevec); Imatinib mesylate 400mg capsule;   D01441
 D08066 
 3件: ABL1, KIT, PDGFRA   3件: Chronic myeloid leukemia, MAPK signaling pathway, Pathways in cancer   11件:
13,
28,
34,
35,
46,
51,
85,
86,
87,
89,
162
 29   Imiquimod  2件: Imiquimod; Imiquimod 5% cream;   D02500   1件: TLR7   1件: Toll-like receptor signaling pathway   1件:
34
 30   Interferon alfa-2b  1件: Interferon alfa-2b;   D02745   2件: IFNAR1, IFNAR2   7件: Cytokine-cytokine receptor interaction, Hepatitis C, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Natural killer cell mediated cytotoxicity, Pathways in cancer, Toll-like receptor signaling pathway   3件:
25,
34,
227
 31   Iodide  3件: Iodide; Oncolytic measles virus encoding thyroidal sodium iodide symporter; Sodium iodide;   -   -   -   1件:
34
 32   Lamotrigine  3件: Lamotrigine; Lamotrigine extended release tablets; Lamotrigine dispers;   D00354   1件: SCN1A   1件: Dopaminergic synapse   3件:
13,
34,
114
 33   Lapatinib  1件: Lapatinib;   D04024
 D08108 
 2件: EGFR, ERBB2   4件: Breast cancer, ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   3件:
34,
74,
75
 34   Lenalidomide  5件: Lenalidomide; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Lenalidomide, dexamethasone and cyclophosphamide;   D04687   1件: TNF   6件: Apoptosis, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, TNF signaling pathway   8件:
16,
26,
28,
34,
49,
96,
284,
300
 35   Lovastatin  5件: Lovastatin; Lovastatin 60 mg; Lovastatin ™; Lovastatin, then minocycline/lovastatin; Minocycline, then minocycline/lovastatin;   D00359   1件: HMGCR   1件: Terpenoid backbone biosynthesis   10件:
6,
34,
46,
79,
156,
160,
195,
206,
263,
310
 36   Methionine  7件: Methionine; [11c]-methionine; C11-methionine; L-methionine; L-methionine ([11c]methyl); S-adenosyl-l-methionine; S-adenosyl-methionine (same) capsules;   D00019
 D04983 
 -   -   6件:
34,
75,
84,
93,
229,
300
 37   Methotrexate  81件: Methotrexate; Intrathecal methotrexate; Methotrexate treatment; Mycophenolate mofetil,methotrexate; Methotrexate 2.5 mg; Methotrexate 25 mg; Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Bms-582949 and methotrexate; Certolizumab pegol + methotrexate (mtx); Cp-690,550 + methotrexate; Etanercept + methotrexate; Etanercept , methotrexate; Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate as methotrexate disodium; Methotrexate capsules; Methotrexate disodium; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Methotrexate and folic acid; Methotrexate lachema 5inj. sol; Etanercept, methotrexate, prednisolone; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Azathioprine or methotrexate; Early immunosuppressants (azathioprine, methotrexate); Methotrexate bellon; Methotrexate bellon 25mg/ml; Clobetasol propionate + methotrexate; Treatment with systemic therapy (methotrexate); Cyclosporin, methotrexate (gvhd prophylaxis);   D00142
 D02115 
 2件: DHFR, DHFR2   2件: Folate biosynthesis, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331
 38   Methylphenidate  11件: Methylphenidate; Methylphenidate (mpd); Methylphenidate hydrochloride; Methylphenidate modified release; Methylphenidate modified release 20 mg; Methylphenidate modified release 30 mg; Methylphenidate modified release 40 mg; D-methylphenidate; Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylphenidate, fluoxetin, risperidone;   D01296
 D04999 
 2件: SLC6A2, SLC6A3   2件: Dopaminergic synapse, Synaptic vesicle cycle   7件:
6,
13,
34,
84,
113,
179,
206
 39   Nilotinib  8件: Cohort 1:nilotinib oral capsules (150mg or 300mg); Cohort 2: nilotinib oral capsules (dose to be determined from cohort 1); Nilotinib; Nilotinib 150mg oral capsule [tasigna]; Nilotinib 300mg oral capsule [tasigna]; Nilotinib 150 mg; Nilotinib hydrochloride monohydrate; Nilotinib (tasigna);   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   4件: Chronic myeloid leukemia, ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   5件:
6,
8,
34,
51,
86
 40   PD-0325901  2件: Pd-0325901; Pd-0325901 oral capsule;   -   -   -   1件:
34
 41   PTC299  1件: Ptc299;   -   -   -   1件:
34
 42   Pirfenidone  6件: Pirfenidone; Pirfenidone and nintedanib; Pirfenidone or nintedanib; Pirfenidoneone; Sub-study: pirfenidone; Pirfenidone 267 mg [esbriet];   D01583   6件: CCL2, IL10, IL1A, IL1B, IL6, TNF   5件: Cellular senescence, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, TGF-beta signaling pathway, TNF signaling pathway   10件:
34,
46,
50,
51,
58,
84,
85,
164,
222,
228
 43   Pomalidomide  4件: Pomalidomide; Pomalidomide and dexamethasone; Pomalidomide (cc-4047; Pomalidomide oral product;   D08976   2件: IL6, TNF   6件: Apoptosis, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway   6件:
28,
34,
51,
85,
227,
331
 44   Propofol  3件: Propofol; Propofol-lipuro; Intubated with propofol (ip);   D00549   16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   2件: GABAergic synapse, Neuroactive ligand-receptor interaction   8件:
6,
21,
22,
34,
46,
84,
98,
296
 45   Ranibizumab  3件: Ranibizumab; Intravitreal injection ranibizumab; Ranibizumab injection (0.5 mg);   D05697   1件: VEGFA   1件: VEGF signaling pathway   4件:
34,
166,
227,
301
 46   Selumetinib  4件: Selumetinib; Selumetinib (azd6244 hyd sulfate) 25mg/m2; Selumetinib (azd6244 hyd sulfate) 50mg/dose; Selumetinib sulfate;   D09666   2件: MAP2K1, MAP2K2   2件: ErbB signaling pathway, MAPK signaling pathway   1件:
34
 47   Simvastatin  16件: Simvastatin; Simvastatine; Encapsulated simvastatin tablets; Simvastatin 40 mg film-coated tablets; Simvastatin alternova; Simvastatina; Simvastatina sandoz 40 mg comprimidos recubiertos con película efg; Simvastatine sandoz 40 mg filmomhulde tabletten; Simvastatine sandoz 40mg deelbare filmomhulde tabletten; Simvastatin 20mg/5ml oral suspension; Ezetimibe+simvastatin drug combination; Simvastatin 40mg; Simvastatin-ratiopharm; Simvastatin-ratiopharm®; Simvastatin treatment for 28 days; Simvastatin susp.;   D00434   1件: HMGCR   1件: Terpenoid backbone biosynthesis   19件:
6,
13,
15,
34,
46,
49,
51,
66,
79,
86,
89,
94,
158,
162,
195,
265,
298,
299,
310
 48   Sirolimus  16件: Sirolimus; Temsirolimus; Temsirolimus tablets; Sirolimus 2 mg; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Sirolimus (formerly known as rapamycin); Sirolimus 2%; Sirolimus, 2%; Rapamycin, sirolimus; Sirolimus and hydroxychloroquine; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 0,1% crème; Sirolimus oral liquid product 1mg/ml; Topical 0.1% sirolimus;   D00753   1件: MTOR   2件: Pathways in cancer, mTOR signaling pathway   36件:
2,
13,
15,
17,
34,
35,
36,
46,
49,
51,
60,
61,
62,
63,
65,
66,
67,
85,
86,
89,
96,
98,
137,
157,
158,
192,
222,
256,
277,
278,
279,
280,
281,
283,
285,
331
 49   Sodium chloride  14件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); Sodium chloride; Sodium chloride solution; Isotonic sodium chloride solution; 0.9% sodium chloride injection; Physiological serum (sodium chloride); Sodium chloride solvent; Sodium chloride solution 0.9%; 0.9% w/v sodium chloride solution; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium pyruvate in 0.9% sodium chloride solution;   D02056   -   -   19件:
6,
11,
13,
14,
17,
34,
46,
51,
53,
67,
78,
86,
97,
168,
193,
227,
228,
288,
299
 50   Sodium iodide  2件: Oncolytic measles virus encoding thyroidal sodium iodide symporter; Sodium iodide;   D04874
 D05328
 D05863 
 -   -   3件:
34,
46,
88
 51   Sorafenib  3件: Nexavar (bay 43-9006) (sorafenib); Sorafenib; Sorafenib (as tosylate);   D06272
 D08524 
 8件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET   7件: ErbB signaling pathway, Hepatocellular carcinoma, MAPK signaling pathway, Pathways in cancer, Renal cell carcinoma, Thyroid cancer, VEGF signaling pathway   2件:
34,
86
 52   Sulfate ion  0件:   -   -   -   22件:
2,
6,
11,
13,
26,
34,
36,
46,
49,
60,
61,
64,
66,
79,
86,
96,
222,
226,
265,
296,
297,
299
 53   Sunitinib  3件: Sunitinib; Sunitinib malate; Sutent®/sunitinib;   D06402
 D08552 
 9件: CSF1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET   3件: MAPK signaling pathway, Pathways in cancer, VEGF signaling pathway   2件:
28,
34
 54   Temozolomide  2件: Temozolomide; Temozolomide (temodar);   D06067   -   -   1件:
34
 55   Temsirolimus  2件: Temsirolimus; Temsirolimus tablets;   D06068   1件: MTOR   3件: ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   4件:
13,
34,
89,
331
 56   Tipifarnib  1件: Tipifarnib;   D03720   2件: FNTA, FNTB   1件: Terpenoid backbone biosynthesis   1件:
34
 57   Trametinib  1件: Trametinib;   D10175   2件: MAP2K1, MAP2K2   4件: ErbB signaling pathway, MAPK signaling pathway, Melanoma, Pathways in cancer   1件:
34
 58   Valproic Acid  3件: Valproic acid; Valproic acid (vpa); Valproic acid and levocarnitine;   D00399   6件: ABAT, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2   2件: Calcium signaling pathway, GABAergic synapse   14件:
2,
3,
5,
8,
26,
34,
65,
89,
90,
102,
222,
233,
256,
331
 59   Vinblastine  3件: Vinblastine; Vinblastine sulfate; Vinblastine sulphate;   D01068
 D08675 
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   1件: Gap junction   1件:
34
 60   Vincristine  3件: Vincristine; Vincristine sulfate; Vincristine sulfate (oncovin);   D02197
 D08679 
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   1件: Gap junction   4件:
26,
34,
61,
331

先頭へ